Tags

Type your tag names separated by a space and hit enter

Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
J Dermatol 2014; 41(3):239-44JD

Abstract

Adult T-cell leukemia-lymphoma (ATL) is one of the most malignant lymphomas with poor prognosis. ATL cells express CC chemokine receptor 4 (CCR4) and mogamulizumab, a monoclonal antibody against CCR4 that exhibits very strong cytotoxicity for ATL cells via antibody-dependent cellular cytotoxicity. Although its effect is dramatic in ATL, serious adverse reactions such as Stevens-Johnson syndrome have been reported. However, these eruptions can appear as therapeutic signs of mogamulizumab. We evaluated the effectiveness of mogamulizumab in five acute-type ATL patients. Peripheral blood (PB) and lymph nodes (LN) were affected in three and four patients, respectively. In PB, complete response (CR) was obtained in all three patients and partial response (PR) was recorded in LN of one patient. In skin lesions, four of five patients manifested CR; in two, the lesions worsened after the start of mogamulizumab treatment and subsequently improved. In these lesions, CD4(+) 8(-) 25(+) ATL cells were replaced by CD3(+) 8(+) cytotoxic T cells. Cutaneous adverse reactions (CAR) developed in two patients with CR; they did not show a relapse of ATL over the course of 9 months. Our findings suggest that mogamulizumab should be continued and surface marker evaluation should be performed even in patients whose skin lesions show aggravation, and that CAR may be a marker for a favorable prognosis.

Authors+Show Affiliations

Department of Dermatology, Imamura Bun-in Hospital, Kagoshima, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

24628073

Citation

Yonekura, Kentaro, et al. "Effect of anti-CCR4 Monoclonal Antibody (mogamulizumab) On Adult T-cell Leukemia-lymphoma: Cutaneous Adverse Reactions May Predict the Prognosis." The Journal of Dermatology, vol. 41, no. 3, 2014, pp. 239-44.
Yonekura K, Kanzaki T, Gunshin K, et al. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol. 2014;41(3):239-44.
Yonekura, K., Kanzaki, T., Gunshin, K., Kawakami, N., Takatsuka, Y., Nakano, N., ... Utsunomiya, A. (2014). Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. The Journal of Dermatology, 41(3), pp. 239-44. doi:10.1111/1346-8138.12419.
Yonekura K, et al. Effect of anti-CCR4 Monoclonal Antibody (mogamulizumab) On Adult T-cell Leukemia-lymphoma: Cutaneous Adverse Reactions May Predict the Prognosis. J Dermatol. 2014;41(3):239-44. PubMed PMID: 24628073.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. AU - Yonekura,Kentaro, AU - Kanzaki,Tamotsu, AU - Gunshin,Kanayo, AU - Kawakami,Nobuyo, AU - Takatsuka,Yoshifusa, AU - Nakano,Nobuaki, AU - Tokunaga,Masahito, AU - Kubota,Ayumu, AU - Takeuchi,Shogo, AU - Kanekura,Takuro, AU - Utsunomiya,Atae, PY - 2013/11/06/received PY - 2014/01/01/accepted PY - 2014/3/18/entrez PY - 2014/3/19/pubmed PY - 2015/4/14/medline KW - adult T-cell leukemia-lymphoma KW - chemokine receptor 4 KW - cutaneous adverse reaction KW - cytotoxic T lymphocyte KW - mogamulizumab SP - 239 EP - 44 JF - The Journal of dermatology JO - J. Dermatol. VL - 41 IS - 3 N2 - Adult T-cell leukemia-lymphoma (ATL) is one of the most malignant lymphomas with poor prognosis. ATL cells express CC chemokine receptor 4 (CCR4) and mogamulizumab, a monoclonal antibody against CCR4 that exhibits very strong cytotoxicity for ATL cells via antibody-dependent cellular cytotoxicity. Although its effect is dramatic in ATL, serious adverse reactions such as Stevens-Johnson syndrome have been reported. However, these eruptions can appear as therapeutic signs of mogamulizumab. We evaluated the effectiveness of mogamulizumab in five acute-type ATL patients. Peripheral blood (PB) and lymph nodes (LN) were affected in three and four patients, respectively. In PB, complete response (CR) was obtained in all three patients and partial response (PR) was recorded in LN of one patient. In skin lesions, four of five patients manifested CR; in two, the lesions worsened after the start of mogamulizumab treatment and subsequently improved. In these lesions, CD4(+) 8(-) 25(+) ATL cells were replaced by CD3(+) 8(+) cytotoxic T cells. Cutaneous adverse reactions (CAR) developed in two patients with CR; they did not show a relapse of ATL over the course of 9 months. Our findings suggest that mogamulizumab should be continued and surface marker evaluation should be performed even in patients whose skin lesions show aggravation, and that CAR may be a marker for a favorable prognosis. SN - 1346-8138 UR - https://www.unboundmedicine.com/medline/citation/24628073/Effect_of_anti_CCR4_monoclonal_antibody__mogamulizumab__on_adult_T_cell_leukemia_lymphoma:_cutaneous_adverse_reactions_may_predict_the_prognosis_ L2 - https://doi.org/10.1111/1346-8138.12419 DB - PRIME DP - Unbound Medicine ER -